Setup News Ticker
Searching for 'talks'. (Return)

Google Market NewsJul 13, 2020
Analog Devices in talks to buy Maxim Integrated for about $20B - Fox Business
Analog Devices in talks to buy Maxim Integrated for about $20B  Fox BusinessAnalog Devices Near Deal to Buy Maxim for $17 Billion  Yahoo! VoicesChip-maker Analog poised to buy rival Maxim Integrated for more than $17 billion  MarketWatchEETimes - Analog Devices, Maxim, Said to Be on the Verge of a $20B Deal -  EE TimesAnalog Devices nears $20bn deal for chip rival Maxim  Financial Times

Google Business NewsJul 12, 2020
Chiefs' Travis Kelce interrupts Patrick Mahomes' interview with wet willy during ACC | NBC Sports - NBC Sports
Chiefs' Travis Kelce interrupts Patrick Mahomes' interview with wet willy during ACC | NBC Sports  NBC SportsWill Patrick Mahomes need six Super Bowls to pass Tom Brady as greatest NFL QB ever? | Get Up  ESPNReport: Chiefs, Chris Jones have begun contract talks  NBC Sports - NFLChiefs' Travis Kelce gave Patrick Mahomes a wet willy during national TV interview  Kansas City StarReading the tea leaves on the Kansas City Chiefs quarterback moves  Arrowhead Addict

Yahoo BusinessJul 12, 2020
Chipmaker Analog Devices in advanced talks to buy Maxim Integrated - sources
(Bloomberg) -- Chinese biotech company Beigene Ltd. plans to raise $2.1 billion in a direct offering of 145.8 million shares to fund drug research and market its treatments in the U.S. and China, said the Nasdaq-listed company on Monday.The shares will be priced at $14.23 each, equivalent to a price of $185 per American Depository Share -- 5.6% lower than its closing price on Friday. The offering is expected to close on or around July 15, said the company, whose shares are also traded in Hong Kong.Buyers in the share sale include investment firm Baker Bros. Advisors LP and American generics giant Amgen Inc., which last year had purchased a 20.5% stake in Beigene for $2.7 billion to jointly develop cancer therapies. China's New Cancer Drugs Are Much Cheaper Than U.S. RivalsThe share sale comes after the Beijing-based company's blood cancer therapy became the first Chinese cancer drug to receive approval from the U.S. Food and Drug Administration last November, positioning Beigene as one of the most promising Chinese biotech companies taking on the world's biggest pharmaceutical firms in medical innovation and scientific research.Investment into Chinese biotech startups is surging as the opening up of the Asian giant's $132 billion pharmaceutical market creates an unprecedented profit-making opportunity for health-care companies. The Amgen stake, one of the first major tie-ups between American and Chinese drugmakers, was widely seen as a vote of confidence in Beigene's pipeline.The company has received appro
Coronaviruscases record reports futures stock
risecoronavirus European shares attention turns
Covid-19cases Fauci Florida record deadline
FundHedge Right Did Make Call
Trumpadministration school wont takes Order
LookMars Here we come fleet
Herewe Look Mars come fleet
amidcoronavirus Disney rise pandemic World
Chinasanctions global Moly strikes $550m
Casescoronavirus record Florida reports South

Top News (Business News)
Accounting Today
AdWeek News
Banking Business Review
Barron's This Week Magazine
Barron's Up and Down Wall Street Daily
Brad Ideas
Chicago Tribune Business News
CNBC Business
CNBC Economy
CNBC Finance
CNN/Money Real Estate News Analysis Indicators
Enterprise Application News
Forbes Headlines
Forbes Social Media News - China, Economy & Trade - Financial Markets - Hedge Funds - Telecoms - US
Google Business News
Google Market News
HBS Working Knowledge
INSEAD Knowledge
International Tax Review
L.S. Starrett News
MarketWatch Breaking News
MarketWatch MarketPulse
McKinsey Quarterly Business
Nielsen Trends
NonProfit Times
NPR Topics: Business
NYTimes Business
Private Equity Breaking News
Reuters Business
Reuters Company News
Reuters Money Updates: News Digest
Tax Policy News
The Economist International News
The Motley Fool
USA Today Money
Wall Street Journal US Business
Wall Street Transcript
Washington Post Business
WSJ Asia
WSJ Europe
WSJ MoneyBeat
WSJ Opinion
WSJ World Markets
Yahoo Business
  • CEOExpress
  • 1 Boston Place | Suite 2600
    Boston MA 02108
  • 617 482 1200
    617 299 8649 (fax)
  • Contact
  • As an Amazon Associate
    CEOExpress earns from
    qualifying purchases.

©1999-2020 CEOExpress Company LLC